Direct Answer
ResMed (RMD) is the global market leader in CPAP machines and sleep apnea management, selling devices, disposable masks (a recurring consumable), and cloud software to patients, home care providers, and healthcare facilities. The Philips Respironics recall (2021) dramatically accelerated ResMed's market share gains. The primary investor debate centers on whether GLP-1 weight-loss drugs (Ozempic, Wegovy) will meaningfully reduce the long-term sleep apnea patient population.
ResMed (RMD) Business & Investor Dossier
Company Snapshot
| Ticker | RMD (NYSE) |
|---|---|
| Founded | 1989 |
| Headquarters | San Diego, California (listed); also Australian HQ in Sydney |
| Sector | Health Care |
| Industry | Health Care Equipment |
| Business | CPAP devices, masks, and out-of-hospital care software for sleep apnea and chronic respiratory conditions |
| Notable | Philips recall windfall; GLP-1 drug overhang; recurring mask consumable revenue; Brightree/MatrixCare software businesses |
| Key Competitors | Philips Respironics, Fisher & Paykel Healthcare, Löwenstein Medical |
What Does ResMed Do?
ResMed sells the machines and masks that sleep apnea patients use every night, plus the software that home health providers and care facilities use to manage chronic conditions outside hospitals. The mask and accessory replacement cycle creates predictable recurring revenue on top of device unit sales. The 2021 Philips recall handed ResMed a multi-year market share opportunity.
Frequently Asked Questions
What does ResMed do and how does it make money?
ResMed is the global leader in devices and software for treating sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions outside of the hospital. The core business is manufacturing CPAP (continuous positive airway pressure) machines and the disposable masks and accessories that patients use nightly. ResMed makes money through three main streams: device sales (CPAP/bilevel machines, ventilators), consumables (replacement masks and accessories, which are replaced regularly and generate recurring revenue), and software/subscription revenue from its digital health platform (myAir for patients, AirView for providers, and the Brightree/MatrixCare business management software used by home health and hospice agencies).
How large is the sleep apnea market opportunity?
Sleep apnea is significantly underdiagnosed, with estimates suggesting that up to 80-90% of people with clinically meaningful sleep apnea remain undiagnosed. This represents a large growth runway for ResMed: as diagnostic awareness improves, sleep study adoption grows (driven by lower-cost home sleep tests), and primary care physicians become better at identifying patients, the diagnosed and treated population grows. The addressable patient population is estimated at 936 million people with moderate-to-severe sleep apnea globally, of whom only a small fraction are currently treated with CPAP. The disease is strongly associated with obesity, cardiovascular disease, diabetes, and cognitive decline, giving it significant public health importance and making it a focus area for healthcare systems trying to reduce downstream costs.
What was the Philips recall and how did it benefit ResMed?
In 2021, Philips Respironics, ResMed's primary direct competitor, announced a massive recall of millions of CPAP, bilevel, and ventilator devices due to potential foam degradation that could produce toxic particles and gases. This was one of the largest medical device recalls in history. Philips had been approximately 30-35% of the CPAP market prior to the recall. As Philips struggled to address the recall, supply constraints, and regulatory investigations, ResMed (as the primary remaining global CPAP manufacturer at scale) captured significant market share. ResMed's revenue growth accelerated sharply in fiscal years 2022 and 2023. The question for investors became whether the demand was durable share gain or temporary recall-driven substitution, and how quickly Philips could return remediated devices to market.
What is ResMed's out-of-hospital care software business?
Beyond devices, ResMed has built a significant software platform for managing care outside hospitals. Brightree (acquired 2016) provides cloud-based business management software for home medical equipment (HME) providers, home health agencies, and hospice providers. MatrixCare (acquired 2018) provides EHR and care management software for senior care facilities (skilled nursing, assisted living, home health). These businesses serve the growing sector of complex care management outside hospital walls. Together, they give ResMed a software-and-services revenue stream that is high-margin, recurring, and somewhat insulated from device market dynamics. The software businesses also increase ResMed's strategic presence with the providers who recommend and supply its devices.
What are the main risks for ResMed?
Key risks include GLP-1 drug impact (obesity drugs like Ozempic and Wegovy cause weight loss, which can reduce sleep apnea severity; if GLP-1 drugs achieve broad adoption and meaningful sleep apnea resolution, the long-term addressable patient pool could be smaller than estimated), Philips re-entry (if Philips successfully remediates its devices and re-enters the CPAP market, some of the market share ResMed gained may reverse), competitive pressure (Fisher & Paykel Healthcare competes in CPAP masks and humidification; Löwenstein Medical and other regional players exist), reimbursement changes (US Medicare/Medicaid CPAP reimbursement rates can be changed by CMS; competitive bidding programs have previously reduced reimbursement), and software competition (Brightree/MatrixCare face competition from larger healthcare IT vendors in home health software).